Given that the deletion of MLIP leads to a downregulation of the FOXO1 pathway, and overexpression of MLIP is likely to have the opposite effect, therapeutics aimed at enhancing MLIP function or expression could potentially restore the normal function of FOXO1 signaling, thereby inhibiting cancer development and progression. The gene discussed is FOXO1; the disease is cancer.